MS drug ocrelizumab gets a Needle-Free makeover: new shot form tested

NCT ID NCT07667322

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it could make treatment much more convenient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ocrelizumab (Ocrevus) given as a shot under the skin
What this could lead to: If successful, this could offer a more convenient way to take ocrelizumab for multiple sclerosis, potentially reducing infusion time and side effects.
What could go wrong: This is an early Phase 1 trial with only 75 people, so safety and effectiveness are not yet proven. The new injection form may cause different side effects or not work as well as the current IV version.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C.

Guadalajara, Jalisco, 44130, Mexico
Centro de Pesquisas Clinicas

São Paulo, São Paulo, 01228-200, Brazil
Hope Neurology

Knoxville, Tennessee, 37922, United States
Inovacion y Desarrollo en ciencias de la salud

Mexico City, Mexico CITY (federal District), 14090, Mexico
Instituto de Neurologia de Curitiba

Curitiba, Paraná, 81210-310, Brazil
John Hopkins University School of Medicine

Baltimore, Maryland, 21287, United States
Morriston Hospital

Swansea, SA6 6NL, United Kingdom
Neurology Associates, PA

Maitland, Florida, 32751, United States
Nottingham University Hospitals NHS Trust

Nottingham, NG7 2UH, United Kingdom
Profound Research, LLC

Carlsbad, California, 92011, United States
Shepherd Center Inc.

Atlanta, Georgia, 30309, United States
University of South Florida

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.